R&D Partner Content 5th Gene Therapy for Ophthalmic Disorders Summit Ophthalmic drug developers are unlocking the full potential of gene therapy.
Partner Content Partner Content Exclusive interview with ForwardVue Pharma released for Opht... Exclusive interview with ForwardVue Pharma
Partner Content Partner Content Ophthalmic Drug Delivery Development - Trials and Tribulatio... Ophthalmic Drug Delivery Development Workshop
Partner Content Partner Content Novel Platforms in Ocular Drug Delivery workshop discussed a... Novel Platforms in Ocular Drug Delivery workshop
Partner Content Partner Content Aerie Pharmaceuticals interview released for Ophthalmic Drug... Ophthalmic Drugs
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
